DIANA technology can be advantegously used not only for effective kinase inhibitor profiling, but any DIANA assay available in our profiling portfolio can be readily transformed into the powerful high-throughput screening (HTS) assay. In this setup, screened compounds compete with the DIANA probe for the target binding. It offers sensitive hit discovery (ultra-low false-positive and false-negative rate) while providing direct quantification of the compound’s inhibition potency (Kd). It also allows highly efficient screening of pooled libraries leading to a reduced screening cost and time. This makes it suitable not only for large pharma high-throughput-screening facilities but also for smaller-scale projects at academic institutions (in-house libraries of ~10k compounds can be screened in just several 384-well plates). Finally, we can also offer a characterization of ADME properties of identified lead compounds that can emerge from the HTS campaigns.
We have a high success rate even or a difficult targets
We are able to provide you the HTS service in 3 months
Assay development available as stand-alone service or as part of collaborative projects
Minimal performance criteria and risk-sharing commercial models possible
Download the complete HTS Leaflet
Document name | Download |
|---|---|
DIANA Technology for HTS
DIANA Biotechnologies offers HTS projects run at their specialized screening facility, utilizing several in-house small-molecule libraries that collectively comprise appoximately 135,000 compounds in following libraries: Drug-like Diversity Set – app. 120 000 compounds (mid MW and logP). Lead-like Diversity Set – app. 10 000 compounds (low MW and logP). FDA library – app. 2800 compounds. Kinase Inhibitor Library – app. 1900 compounds. Customer or third-party compound libraries are also accepted, and compounds can be screened in pooled setups for easier logistics and higher confidentiality. The assay provides accurate inhibition potency measurements, with hits ranked by affinity and validated using known inhibitors. Full data analysis and interpretation are included, with short turn-around times and competitive pricing.
